Skip to content

Point of Care Rapid STI Test Optimization and Validation Extension

Validation of Selected Point of Care Rapid STI Diagnostic Tests for Laboratory Based and Self- Test Use - A Sub-Study of Acceptability Research on Integrated Point of Care Sexually Transmitted Infection (STI) Testing and Expanded Partner Therapy (EPT) (ARISE)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06566677
Acronym
PROVE
Enrollment
364
Registered
2024-08-22
Start date
2023-01-26
Completion date
2023-12-07
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chlamydia Trachomatis Genital Infection, Gonorrhea, Trichomoniasis

Brief summary

The purpose of this sub-study (PROVE) is to support and facilitate the validation of commercially available point of care (POC) sexually transmitted infection (STI) diagnostic test kits/devices for potential on-site laboratory use as well as bedside use in parallel to gold standard established testing methodologies. A further extension of bedside testing would include self-testing.

Detailed description

Screening and Enrolment procedures for the ARISE study (HREC Ref No. 210614) involves adolescent girls and young women (AGYW) being screened for Neisseria gonorrhoea (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) as determined through testing of clinician-collected genital swabs followed by GeneXpert, OSOM rapid TV testing or through wet mount visualisation of the micro-organisms of interest. This will generate a pool of AGYW with known STI diagnoses who, if positive, will be treated on-site on the day of STI detection. It will also create an ideal opportunity to leverage access to samples from willing participants (prior to STI treatment if STI positive) for validation of a range of alternate STI test kits. Samples provided will enable same-day parallel testing on additional platforms for validation of the sensitivity and specificity of these alternate tests against the known validated platformsThis initiative will expand the menu of cost effective and user friendly STI test kits that may ultimately be used in other research studies, in public clinic settings and as self-tests performed discretely in the convenience and privacy of one's home.

Interventions

None listed

Sponsors

University of Washington
CollaboratorOTHER
Wits RHI Research Centre Clinical Research Site
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

Participants must meet the following criteria to be eligible for inclusion in the study: * Cisgender adolescent girls and young women (18-25 years of age, inclusive), screened for or enrolled in the ARISE study. * Willing to provide written informed consent to participate in this sub-study. * Willing to provide additional samples including vaginal and endocervical swabs, urine and those collected through the use of tampons and disposable menstrual cups.

Exclusion criteria

* Cisgender male or transgender woman or transgender man * Age \<18 years * Unable or unwilling to provide written informed consent * Have any condition that in the opinion of the investigators will interfere with successful completion of sub-study procedures

Design outcomes

Primary

MeasureTime frameDescription
GeneXpert1 yearA PCR instrument was used to assess the presence of chlamydia trichomatis and gonorrhea from samples taken using endocervical swabs.

Secondary

MeasureTime frameDescription
Osom rapid testing kit1 yearA rapid point-of-care test for the diagnosis of Trichomonas vaginalis in women using dacron swabs.

Other

MeasureTime frameDescription
Cromatest Chlamydia one step rapid kit1 yearFemale cervical swab and male urethral swab specimens to diagnose chlamydia
NADAL Chlamydia Test1 yearFemale or male urethral swab/male Urine used to diagnose chlamydia
JD Biotech Trichomonas vaginalis antigen rapid test kit1 yearTrichomonas vaginalis antigen rapid test kit
Rapid Labs Gonorrhea1 yearSterile Female cervical swab/ male urethral swab to diagnose gonorrhea
ACRO Biotech Gonorrhoea1 yearFemale cervical swab/ male urethral swab to diagnose gonorrhoea
JD Biotech C. Trachomatis/ N. Gonorrhoeae Ag combo rapid test1 yearUrine or vaginal cavity swab or vaginal glans sample to diagnose chlamydia trichomati and gonorroea

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026